(19)
(11) EP 4 034 160 A1

(12)

(43) Date of publication:
03.08.2022 Bulletin 2022/31

(21) Application number: 20775412.8

(22) Date of filing: 14.09.2020
(51) International Patent Classification (IPC): 
A61K 39/395(2006.01)
C07K 16/30(2006.01)
A61K 39/00(2006.01)
C07K 16/28(2006.01)
A61P 35/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 39/39558; C07K 16/2896; C07K 16/3007; C07K 2317/33; A61P 35/00
(86) International application number:
PCT/IB2020/058523
(87) International publication number:
WO 2021/059075 (01.04.2021 Gazette 2021/13)
(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(30) Priority: 27.09.2019 US 201962907224 P

(71) Applicant: Janssen Biotech, Inc.
Horsham, PA 19044 (US)

(72) Inventors:
  • BLACKWELL, Wendell Lamar B
    Skillman, New Jersey 08558 (US)
  • DOLFI, Douglas V.
    Norristown, Pennsylvania 19403 (US)
  • LOWENSTEIN, Cassandra L.
    Spring House, Pennsylvania 19477 (US)
  • VERONA, Raluca I.
    Spring House, Pennsylvania 19477 (US)

(74) Representative: Carpmaels & Ransford LLP 
One Southampton Row
London WC1B 5HA
London WC1B 5HA (GB)

   


(54) ANTI-CEACAM ANTIBODIES AND USES THEREOF